Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 17/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9185372 | 1.00 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL8078188 | 1.00 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL6604556 | 1.00 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL13875665 | 1.00 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL472020 | 1.00 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL14364969 | 1.00 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL6135633 | 1.00 | TACR1 (0.55) | TACR1NPC1MTORRAB9A | |
| SCHEMBL7121023 | 0.90 | TACR1 (0.49) | TACR1NPC1MTORRAB9A | |
| SCHEMBL9537788 | 0.87 | TACR1 (0.46) | TACR1 | |
| SCHEMBL9532928 | 0.87 | TACR1 (0.46) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112557541-B | Detection method of maropiptan citrate and related substances thereof | 河北科技大学 | 2022-07-12 | — | — | CN | disclosed |
| EP-1551833-A1 | PROCESS FOR THE PREPARATION OF (S,S)-CIS-2-BENZHYDRYL-3-BENZYLAMINOQUINUCLIDINE | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20050085641-A1 | Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine | PFIZER INC. | 2005-04-21 | — | — | US | disclosed |
| US-6861526-B2 | Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine | PFIZER INC. (US) | 2005-03-01 | — | — | US | disclosed |
| EP-0917869-B1 | Use of water-in-oil emulsions as thickening agents in cosmetical and pharmaceutical compositions | BASF AG (DE) | 2005-01-26 | — | — | EP | disclosed |
| US-20040116704-A1 | Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine | PFIZER INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004035575-A1 | PROCESS FOR THE PREPARATION OF (S,S)-CIS-2-BENZHYDRYL-3-BENZYLAMINOQUINUCLIDINE | PFIZER PRODUCTS, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| EP-1114823-A2 | Substituted benzylamino nitrogen containing non-aromatic heterocycles | PFIZER INC. (US) | 2001-07-11 | — | — | EP | disclosed |
| EP-0917869-A2 | Use of water-in-oil emulsions as thickening agents in cosmetical and pharmaceutical compositions | BASF AKTIENGESELLSCHAFT (DE) | 1999-05-26 | — | — | EP | disclosed |
| EP-0783535-B1 | PROCESS FOR PREPARING AQUEOUS SOLUTIONS OF POLY(N-VINYL-EPSILON-CAPROLACTAM) AND THEIR USE | BASF AG (DE) | 1998-05-13 | — | — | EP | disclosed |
| EP-0655996-A1 | SUBSTITUTED BENZYLAMINO NITROGEN CONTAINING NON-AROMATIC HETEROCYCLES | PFIZER INC. (US) | 1995-06-07 | — | — | EP | disclosed |
| WO-1994004496-A9 | SUBSTITUTED BENZYLAMINO NITROGEN CONTAINING NON-AROMATIC HETEROCYCLES | — | 1995-01-26 | — | — | WO | disclosed |
| WO-1994004496-A1 | SUBSTITUTED BENZYLAMINO NITROGEN CONTAINING NON-AROMATIC HETEROCYCLES | PFIZER INC. (US) | 1994-03-03 | — | — | WO | disclosed |
| EP-0409931-B1 | QUINUCLIDINE THERAPEUTIC AGENTS | PFIZER (US) | 1994-02-16 | — | — | EP | disclosed |
| US-5162339-A | Substance P Antagonists, Gastrointestinal and Central Nervous System Disorders, Antiinflammatory Agents, Analgesics | PFIZER INC. (US) | 1992-11-10 | — | — | US | disclosed |
| EP-0409931-A1 | QUINUCLIDINE THERAPEUTIC AGENTS. | PFIZER (US) | 1991-01-30 | — | — | EP | disclosed |
| WO-1990005729-A1 | QUINUCLIDINE THERAPEUTIC AGENTS | PFIZER INC. (US) | 1990-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085641-A1 | Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine | BCKDK, SRM, SKP1 | TACR1 1140/4885NPC1 2728/4885MTOR 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.